Pembrolizumab Combination Granted Accelerated Approval for Non-Small Cell Lung Cancer 

Prostate cancer: Blood test could help target treatment 
May 15, 2017
New multiple sclerosis treatment offers breakthrough for patients
May 15, 2017
Show all

Pembrolizumab Combination Granted Accelerated Approval for Non-Small Cell Lung Cancer 

Pembrolizumab (Keytruda) was granted accelerated approval by the FDA in combination with pemetrexed and carboplatin to treat patients with previously untreated metastatic non-squamous non-small cell lung cancer (NSCLC).

The approval was based on findings from the multicenter, multi-cohort KEYNOTE-021 study, which included 123 treatment-naive patients with locally advanced or metastatic non-squamous NSCLC.

Participants were randomized to receive either 200 mg of pembrolizumab every 3 weeks combined with pemetrexed and carboplatin (PC) for 4 cycles followed by pembrolizumab for a maximum of 24 months, compared with PC alone.

At the investigators’ discretion, patients in both groups could receive pemetrexed as maintenance therapy, according to a press release.

The results of the study showed an improvement in overall response rate (ORR) and in progression-free survival (PFS) for patients administered pembrolizumab plus PC. The ORR was 55% in the pembrolizumab plus PC arm and 29% for the PC alone arm. –

See more at: https://www.specialtypharmacytimes.com/news/pembrolizumab-combination-granted-accelerated-approval-for-non-small-cell-lung-cancer#sthash.ft784CWv.dpuf

Read Full Article: Pembrolizumab Combination Granted Accelerated Approval for Non-Small Cell Lung Cancer 

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.